摘要
目的探讨中国人群使用心律平与胺碘酮治疗阵发性室上性心动过速的疗效及安全性。方法采用RevMan5.1.4版本软件中的Meta分析,对2011年8月以前有关中国人群使用心律平与胺碘酮治疗阵发性室上性心动过速的疗效及安全性的文献进行综合分析。结果检索并纳入文献8篇,患者561例。心律平与胺碘酮治疗阵发性室上性心动过速的有效率及不良反应发生率的合并优势比(95%可信区间)分别为0.84(0.40～1.78,P=0.65)与1.17(0.76～1.79,P=0.48)。结论基于目前的研究发现,中国人群使用心律平与胺碘酮治疗阵发性室上性心动过速的有效率及不良反应发生率差异均无统计学意义,临床上可根据患者病情酌情使用。
Objective To evaluate the efficacy and safety of Propafenone and Amiodarone in treating Chinese paroxysmal supraventricular tachyeardia （PSVT） cases. Methods We performed the meta-analysis synthesizing the data from previous published studies （up to August 2011 ） to evaluate the efficacy and safety of Propafenone and Amiodarone in Chinese PSVT cases. Meta-analysis was done using software Review Manager（Version 5.1.4）. Results A total of 8 studies including 561 Chinese cases were identified. The combined ORs（95%CI） of clinical efficiency and incidence of adverse reactions were 0.84 （0.40-1.78, P=0.65） and 1.17 （0.76-1.79,P=0.48）. Conclusions For Chinese population, the chnical efficiency and incidence of adverse reactions of Propafenone and Amiodarone in treating PSVT were similar. The selection of these two drugs should be based on the patient＇s condition.
出处
《循证医学》
CSCD
2013年第3期152-156,共5页
The Journal of Evidence-Based Medicine
